503A Bulk Substance Eligibility: A Pharmacy Checklist
A supplier catalog is not an eligibility determination. Before a pharmacy purchases a bulk substance, its pharmacist and compliance reviewer should document why the exact substance and intended preparation meet the applicable requirements.
Start with the exact substance
Record the chemical name, salt or base form, grade, intended preparation and proposed manufacturer. Similar names are not interchangeable. An assessment of one form does not establish eligibility for another, and a product marketed as research material is not made suitable for patient compounding by a purity percentage.
Understand the statutory pathways
Under section 503A, bulk drug substances must meet the applicable USP or NF monograph requirements if a monograph exists. If no applicable monograph exists, the substance must be a component of an FDA-approved drug; if neither condition applies, it must appear on the 503A bulks list developed through regulation. Other statutory requirements still apply. Do not reduce the review to a single list search.
Separate nominations from an established pathway
A substance nominated for evaluation is not automatically included on the final 503A bulks list. FDA also describes interim enforcement policies for certain nominated substances. Those policies have conditions and are not approvals or general permissions to compound. Record the current policy, substance category, conditions and your reviewer’s reasoning rather than accepting a supplier’s “nominated” badge.
Check the requirements beyond the substance
Eligibility is not the whole compounding assessment. Review patient-specific prescription requirements, restrictions on essentially copies of commercially available drugs, applicable withdrawn-or-removed drug restrictions, manufacturer registration, a valid certificate of analysis and state requirements. FDA shortage status and enforcement policies can change; a local backorder is not evidence of federal shortage status.
Create an eligibility decision record
For each proposed API, record the identity and form, applicable monograph or other statutory pathway, source URLs, date checked, relevant restrictions, proposed use, unresolved questions and approving pharmacist. Keep the determination separate from the supplier quote. If the evidence is incomplete, pause procurement instead of treating silence as clearance.
Reassess when a material fact changes
Repeat the review when the chemical form, intended preparation, supplier or relevant FDA position changes. Use a dated record so another pharmacist can see what was reviewed and why. Do not describe an old assessment as a permanent authorization.
Connect eligibility to supplier qualification
After the eligibility decision, evaluate the source and lot documentation using our bulk API chain-of-custody checklist. Our 503A bulk API purchasing page and pharmacy sourcing hub describe the inquiry route, not a guarantee that a substance is eligible. For a framework comparison, read the 503A versus 503B operator guide.
Sources and limits
FDA: bulk drug substances used under section 503A. Review the linked current lists and policies, not just summaries. This is procurement education, not legal advice or a product eligibility certification.